Testing of dioxolan-methyl-metaacrylate (DMA) for hepatotoxicity and nephrotoxicity

Dioxolan-methyl-metaacrylate (DMA) is applied as an adhesive for optical glasses and as a tooth filling material using the polymerisation properties. In rat LD50 was estimated at about 500 mg/100 g b.m. following i.p. or i.m. administration without distinct sex differences. DMA is less toxic following oral administration. Hypnotic or myorelaxing effects could be observed in a dose-dependent manner. DMA antagonized pentetrazole-induced convulsions. Prolongation of hexobarbital sleeping time without influence on awakening concentration of hexobarbital inhibition of biotransformation reactions, proved in vivo and in in vitro experiments measuring ethylmorphine-N-demethylation, ethoxycoumarin-O-deethylation and cytochrome P-450 content. There are no influences of DMA on urine concentrating ability. Oliguric effects of DMA might be caused by central depressive effects of DMA. There are no distinct effects of DMA on p-aminohippurate transport. Signs of a selective hepatotoxic or nephrotoxic effectiveness of DMA can be excluded because the respective functions were altered only following administration of extremely high doses of DMA (50% of LD50 values).